Efficacy and safety of boosted transarterial radioembolization in patients with chemoembolization-refractory hepatocellular carcinoma
Acta Radiologica · 2026
DOI: 10.1177/02841851261468006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Radiologica, 2026. Verfasst von Gun Ha Kim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Radioembolization, Therapeutic, Chemoembolization, Therapeutic. Die Arbeit nennt 33 Literaturangaben.
Abstract (Originalsprache)
Background
Repeated transarterial chemoembolization (TACE) may lead to treatment refractoriness, in which tumors fail to respond despite technically adequate procedures. However, evidence to guide optimal management strategies for patients with TACE-refractory hepatocellular carcinoma (HCC) remains limited.
Purpose
To assess the efficacy and safety of boosted transarterial radioembolization (TARE) in patients with TACE-refractory HCC. Material and Methods A total of 41 consecutive patients with TACE-refractory HCC underwent boosted TARE between November 2021 and December 2025. Tumor response, time to local tumor progression (TTLTP), time to progression (TTP), overall survival (OS), and adverse events were retrospectively analyzed.
Results
In total, 41 patients (36 men; mean age=66.1 ± 9.3 years) were evaluated. The median number of prior TACE sessions was 4 (range=2–11). Best index tumor response was complete response in 31 (75.6%) patients, partial response in 6 (14.6%), and stable disease in 3 (7.3%), yielding an objective response rate of 90.2%. Median TTLTP was not reached at the time of analysis. Median TTP was 6.5 months (95% confidence interval [CI]=3.1–8.8). Median OS was 31.8 months (95% CI=19.4–not reached). Among 25 patients with disease beyond the Milan criteria, 20 (80.0%) were successfully downstaged to within the Milan criteria, of whom seven subsequently underwent curative-intent surgery. Longer OS was observed in surgical patients compared with non-surgical patients ( P = .048). Severe adverse events occurred in 4 (9.8%) patients. One patient died from sepsis after tumor rupture.
Conclusion
Boosted TARE may provide favorable local tumor control in selected patients with TACE-refractory HCC. Careful patient selection and dosimetry remain essential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
ORCID-Profile: Jin Hyoung Kim, Dong Il Gwon
Zitieren
APA
Kim, G. H., Ko, E., Kim, J., Oh, M., Sung, C., Kim, J. H., & Gwon, D. I. (2026). Efficacy and safety of boosted transarterial radioembolization in patients with chemoembolization-refractory hepatocellular carcinoma. Acta Radiologica. https://doi.org/10.1177/02841851261468006
Vancouver
Kim GH, Ko E, Kim J, Oh M, Sung C, Kim JH, et al. Efficacy and safety of boosted transarterial radioembolization in patients with chemoembolization-refractory hepatocellular carcinoma. Acta Radiologica. 2026. doi:10.1177/02841851261468006
BibTeX
@article{Kim2026,
author = {Kim, Gun Ha and Ko, Eunbyeol and Kim, Jeongyeon and Oh, Minyoung and Sung, Changhwan and Kim, Jin Hyoung and Gwon, Dong Il},
title = {Efficacy and safety of boosted transarterial radioembolization in patients with chemoembolization-refractory hepatocellular carcinoma},
journal = {Acta Radiologica},
year = {2026},
doi = {10.1177/02841851261468006}
}
EUVIMED